0 results available. Select is focused ,type to refine list, press Down to open the menu,
Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. The company’s lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides c...
The following section summarizes insights on Nutriband Inc's EPS Forecast Median Consensus:
To view the full list of supported financial metrics please see Complete Metrics Listing.
Metrics similar to EPS Forecast Median Consensus in the forecast category include:
The median EPS Forecast submitted by any analyst for the company.
The chart above depicts the distribution of eps forecast median consensus for companies operating in the Healthcare sector in the Developed economic region. Over 1,570 companies were considered in this analysis, and 1,513 had meaningful values. The average eps forecast median consensus of companies in the sector is -0.29 with a standard deviation of 4.12.
Nutriband Inc's EPS Forecast Median Consensus of - ranks in the - percentile for the sector. The following table provides additional summary stats:
Economic Risk Region | Developed |
Total Constituents | 1,577 |
Included Constituents | 1,513 |
Min | -21.70 |
Max | 20 |
Median | -0.20 |
Mean | -0.29 |
Standard Deviation | 4.12 |
You can find companies with similar eps forecast median consensus using this stock screener.